조니사미드
조니사미드 · ZON · ci-912 · ad-810 · pd110843 · excegram · exceglan · Excegran
식별자 및 물리적 특성
| CAS No. | 68291-97-4 |
|---|---|
| 분자식 | C8H8N2O3S |
| 평균 분자량 | 212.23 g/mol |
| 단동위원소 질량 | 212.0255633 g/mol |
| SMILES | NS(=O)(=O)Cc1noc2ccccc12 |
| InChIKey | UBQNRHZMVUUOMG-UHFFFAOYSA-N |
| PubChem CID | 5734 |
| ChEMBL | CHEMBL750 |
| ChEBI | CHEBI:10127 |
| EC No. | 614-395-8 |
| DTXSID | DTXSID9046023 |
| 현지명 | 조니사미드 |
화학 및 물리적 성질
| XLogP | 0.2 |
|---|---|
| 극성 표면적 | 94.6 |
| 수소 결합 공여자 수 | 1 |
| 수소 결합 수용자 수 | 5 |
| 회전 가능 결합 수 | 2 |
| 무거운 원자 수 | 14 |
| 형식 전하 | 0 |
| 복잡도 | 298 |
| LogP(분배 계수) | 0.5log Kow = 0.36 /Estimated/ |
| 냄새 | Odorless |
| 맛 | Tasteless |
| Color/Form | White needles from ethyl acetate |
| 용해도 | 0.8Sparingly sol in chloroform, n-hexane. Sol in methanol, ethanol, ethyl acetate, and acetic acid.In water, 0.80 mg/L, temp not specified2.09e+00 g/L>31.8 [ug/mL] (The mean of the results at pH 7.4)H2O: >5 mg/mL, 용해성 |
| 녹는점 | 161-163 °C160-163 °C161 - 163 °C275°C dec. |
| 증기압 | 3.3X10-6 mm Hg at 25 °C /Estimated/ |
| 헨리 상수 | Henry's Law constant = 4.9X10-11 atm-cu m/mole at 25 °C /Estimated/ |
| Physical Description | Solid |
| Dissociation Constants | 10.2pKa = 10.2 |
| Kovats Retention Index | 2022.9 |
| Other Experimental Properties | Hydroxyl radical reaction rate constant = 3.0X10-11 cu cm/molecule sec at 25 °C /Estimated/ |
| 끓는 점 | 223°C (rough estimate) |
| 밀도 | 1.4306 (rough estimate) |
| 굴절률 | 1.5690 (estimate) |
| 인화점 | 9℃ |
| 저장 조건 | Keep in dark place,Sealed in dry,2-8°C |
| 물리적 상태 | 고체 |
| pKa(산도 계수) | 10.2(at 25℃) |
| 색상 | 회백색 |
| Merck | 14,10192 |
| 주요 응용 | 의약품(소분자) |
| InChI | 1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12) |
| InChIKey | UBQNRHZMVUUOMG-UHFFFAOYSA-N |
| SMILES | [S](=O)(=O)(N)Cc1n[o]c2c1cccc2 |
화학적 성질
Off-White Powder
안전 및 규제
| GHS 분류 | WarningH302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]H361 (58.6%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]P203, P264, P270, P280, P301+P317, P318, P330, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 99 reports by companies from 9 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. |
|---|---|
| FDA 요건 | The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl zonisamide, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. |
| Hazard Classes and Categories | Acute Tox. 4 (100%)Repr. 2 (58.6%) |
| 처리 방법 | SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational exposure or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air qualitypotential migration in soil or watereffects on animal, aquatic, and plant lifeand conformance with environmental and public health regulations. |
| Treatment | No specific antidotes for Zonisamide overdosage are available. Following a suspected recent overdose, emesis should be induced or gastric lavage performed with the usual precautions to protect the airway. General supportive care is indicated, including frequent monitoring of vital signs and close observation. (L1712) |
| 상호 작용 | Additive sedation effects may occur /when other CNS depression-producing medications are used with zonisamide/.Effects of Zonegran on the pharmacokinetics of other antiepilepsy drugs (AEDs): Zonisamide had no appreciable effect on the steady state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials. Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro. |
용도
개요
Zonisamide is a broad-spectrum antiepileptic effective in the treatment of refractory seizures. In cultured spinal cord neurons, zonisamide blocks the sustained firing of action potentials induced by depolarizing steps of current injected across the membrane.
용도
Sulfonamide antiseizure agent; blocks repetitive firing of voltagesensitive sodium channels and reduces voltage-sensitive T-type calcium currents. Heterocyclic methanesulfonide with anticonvulsant pro perties. The compound is under investigation for potential therapeutic use as an antiepileptic drug. Anticonvulsant.
일반 설명
Zonisamide, a sulfonamide-type anticonvulsant was recentlyapproved for adjunctive therapy in the treatment ofpartial seizures in adults with epilepsy.Zonisamide isprimarily metabolized by reductive ring cleavage of the 1,2-benzisoxazole ring to 2-sulfamoyl-acetyl-phenol. This biotransformation is mainly carried out by theintestinal bacteria rather than the mammalian cytosolicaldehyde oxidase suggested earlier.Again, because ofthe presence of a sulfonamide moiety in zonisamide molecule,precaution should be given to patients who have ahistory of hypersensitivity reactions toward sulfonamidedrugs and concomitant use of zonisamide with other carbonicanhydrase inhibitors should also be avoided.